Ndhlovu Lishomwa C 4

What Happened

• Director Ndhlovu Lishomwa C received a derivative equity award on March 20, 2026, covering 574,385 shares. The grant is reported at $0.00 (no cash paid at grant) and is an annual 2026 award approved by CytoDyn’s Compensation Committee under the company’s 2012 Equity Incentive Plan.

Key Details

• Transaction date: 2026-03-20; Form 4 filed: 2026-03-24 (timely within the Form 4 filing window).
• Transaction type: Award/Acquisition (derivative instrument—stock option).
• Shares granted: 574,385; reported price at grant: $0.00.
• Vesting: The award will vest in approximately 12 equal monthly installments beginning April 2026 through March 2027 (per footnote).
• Plan: Award issued from shares reserved under the Issuer’s 2012 Equity Incentive Plan.
• Shares owned after transaction: Not specified in the provided filing.

Context

• This is a compensation grant (not an open-market purchase or sale). Such awards are common for executives and directors and do not necessarily indicate immediate buying or selling pressure — the options must vest (per schedule) before they can be exercised or sold.
• For retail investors, outright purchases or sales by insiders typically carry clearer market signals than routine compensation grants.